Abstract: SA-PO0520
Glycemic Control and Subclinical Kidney Injury in Patients Enrolled in a Nephroprotection Program
Session Information
- CKD: Clinical - Therapies, CKM Health, Special Populations, and More
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: CKD (Non-Dialysis)
- 2202 CKD (Non-Dialysis): Clinical, Outcomes, and Trials
Authors
- Anaya Zuluaga, Giselle Elaine, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Restrepo Berdejo, Juan Camilo, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Vargas Lozano, Maria Clara, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Iguaran Garzon, Marcia Fatima, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Martinez Parra, Daniela Sofia, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Botero-Alonso, Daniel Alejandro, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Conde Rivera, Monica Tatiana, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Donado Mercado, Anabell, Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
- Gonzalez Torres, Henry J., Universidad Simon Bolivar, Barranquilla, Atlántico, Colombia
Background
Poor glycemic control is a major driver of chronic kidney disease (CKD) progression in patients with diabetes mellitus. However, the relationship between glycemic status and early markers of renal injury among patients enrolled in nephroprotection programs remains insufficiently characterized. We evaluated the association between glycemic control and clinical, metabolic, renal, and cardiovascular parameters in patients with diabetes enrolled in a nephroprotection program.
Methods
We conducted a cross-sectional study including 486 patients with diabetes enrolled in a nephroprotection program. Patients were classified according to glycemic control status as controlled (HbA1c <7%) or uncontrolled (HbA1c ≥7%). Clinical, anthropometric, laboratory, urinary, and electrocardiographic variables were analyzed. Continuous variables were compared using the Wilcoxon rank-sum test, and categorical variables using Chi-square or Fisher’s exact tests. Statistical significance was defined as p<0.05.
Results
Among 486 patients, 209 (43%) had controlled glycemia and 277 (57%) were uncontrolled. CKD prevalence was significantly higher in uncontrolled patients (96% vs. 90%; p=0.004). Hypertension was more frequent in controlled patients (78% vs. 67%; p=0.012). Total cholesterol levels were significantly lower in controlled patients (172.5 vs. 190 mg/dL; p=0.026), while no significant differences were observed for HDL, LDL, hemoglobin, albumin, phosphorus, or parathyroid hormone levels. Markers of renal injury differed significantly according to glycemic status. Uncontrolled patients presented higher 24-hour proteinuria (13.0 vs. 10.5 mg/24h; p=0.009), albuminuria (11.3 vs. 9.1 mg/L; p=0.018), glucosuria (45% vs. 14%; p<0.001), and urinary protein positivity (9.0% vs. 3.3%; p=0.012). Serum creatinine and estimated glomerular filtration rate did not differ significantly between groups.
Conclusion
Poor glycemic control was significantly associated with markers of subclinical renal injury despite preserved global renal function. Patients with HbA1c ≥7% exhibited higher proteinuria, albuminuria, and glucosuria, suggesting greater glomerular and tubular injury associated with persistent hyperglycemia. These findings reinforce the importance of glycemic control as a key strategy for early nephroprotection in patients with diabetes and high renal risk.